Introduction
============

Efficacious treatment remains elusive for mitigating the devastating neurologic deficit associated with subarachnoid hemorrhage (SAH; [@B16]). The complexity of identifying potential treatments is exasperated by the multiple impactful factors which negatively impact neurologic outcome ([@B13]; [@B15]).

To understand the relative roles of these multiple factors in SAH-induced pathobiology the involvement of these factors has been differentiated by the time courses for their appearances relative to the initiation of SAH: acute, early, and late ([@B15]). Amongst the late developing contributory factors thought to negatively impact neurologic outcome is spasm of cerebral arteries ([@B10]; [@B37]; [@B13]; [@B12]; [@B15]).

Substances implicated in this relatively late developing vasospasm include vasoconstrictor factors released from and formed in response to the hemorrhaged blood, including inhibitors of nitric oxide, such as hemoglobin, and vasoconstrictors, such as endothelin-1, as well as bilirubin oxidation products (BOXes; [@B9]; [@B10]); it should be noted that the abbreviation, "BOXes," was defined as "...the plural form of BOX A \[4-methyl-5-oxo-3-vinyl-(1,5-dihydropyrrol-2-ylidene)acetamide\] and BOX B \[3-methyl-5-oxo-4-vinyl-(1,5-dihydropyrrol-2-ylidene)acetamide\]" ([@B9]), but has evolved to connote bilirubin oxidation products in general (e.g., [@B18]; [@B24]; [@B35]). Indeed, seminal findings from the Clark laboratory (for reviews see, [@B9]; [@B30]) provide key evidence related to the (1) presence of BOXes in the cerebral spinal fluid (CSF) of SAH patients and (2) ability of exogenous BOXes to elicit vasoconstriction. Thus, a pathway was proposed whereby BOXes are formed from the oxidation of heme which is eventually released from the hemorrhaged blood (Figure 1 as adapted from [@B9]).

In fact, for the most part, these earlier studies (e.g., [@B22]; [@B28]; [@B9]) represent the sole findings with respect to this widely referenced hypothesis (e.g., [@B10]; [@B37]; [@B4]; [@B39], [@B38]; [@B13]; [@B11]; [@B15]). Undoubtedly, contributing to the sparsity of follow-up studies with respect to the role of BOXes in SAH-induced spasm has been the difficulty in synthesizing sufficient amounts of chemically pure BOXes species implicated in vasospasm along with a sensitive assay for the measurement of endogenously formed BOXes species. However, in view of the recent total chemical synthesis of BOXes implicated in vasospasm, BOX A and BOX B ([@B21]; [@B34]; **Figure [1](#F1){ref-type="fig"}**), along with sensitive assay methodology for their measurement ([@B36]), it appears that the role of BOXes in SAH-induced spasm is at a juncture for significant further elucidation.

![Subarachnoid hemorrhage (SAH) results in the accumulation of blood in the cerebral spinal fluid (CSF) and the eventual formation of bilirubin oxidation products (BOXes) through the following series of events: lysis of red blood cells in the blood clot, release of heme, oxidation of heme by heme oxygenase 1 (HO-1) and heme oxygenase 2 (HO-2) to form biliverdin, reduction of biliverdin by biliverdin reductase to form bilirubin, oxidation of bilirubin (and oxidation of heme and biliverdin) by oxygen free radicals to form BOXes. BOXes, which includes *Z*-BOX A (4-methyl-5-oxo-3-vinyl-(1,5-dihydropyrrol-2-ylidene)acetamide), *Z*-BOX B (3-methyl-5-oxo-4-vinyl-(1,5-dihydropyrrol-2-ylidene)acetamide), MVM (4-methyl-3-vinylmaleimide) and other compounds cause cerebral pathobiologic effects including spasm of the vasculature, increased stress in neural and vascular tissue, and cellular damage ([@B7]; [@B9]; [@B30]; figure adapted from [@B9]; specification of the *Z* regio-isomers of BOX A and BOX B based on [@B36]).](fphar-09-00303-g001){#F1}

Thus, this perspective critically reviews the key findings supportive of a role for BOXes in SAH-induced vasospasm: the presence of BOXes in the CSF following SAH and the effects of exogenous BOXes on cerebral vascular contractility. Based on this critical evaluation, gaps remaining to be filled are identified and recent approaches that will address these gaps detailed. In this regard, for detailed descriptions of the mechanism whereby BOXes are formed following SAH and the associated pathobiologic effects other than vasoconstriction, including increased stress in neural and vascular tissue and cellular damage, as well as the role of BOXes in the pathobiology associated with another cerebral injury, intracerebral hemorrhage, the reader is referred to other reports and reviews ([@B9]; [@B25]; [@B30]; [@B24]).

Endogenous Boxes
================

The presence of vasoconstrictor factors in the CSF from SAH patients was suggested some four decades ago ([@B3]). More than two decades later it was further suggested that these factors include BOXes ([@B22]; [@B9]). However, the sole report which attempted to identify the BOXes species potentially responsible for the vasoconstriction actually considered the compound identification as preliminary ([@B22]). Specifically, assay of BOX A, BOX B, and MVM (4-methyl-3-vinylmaleimide; **Figure [1](#F1){ref-type="fig"}**) from CSF of SAH patients (extracted with chloroform followed by *in vacuo* evaporation of the chloroform, reconstitution in acetonitrile/water and subjected to reversed-phase HPLC) yielded peaks with similar retention times as BOX A, BOX B, and MVM (obtained from a reaction mixture containing bilirubin and hydrogen peroxide; data not shown; [@B22]). Furthermore, doping the CSF with BOX A resulted in comigration with the corresponding peak (data not shown; [@B22]). Indeed, it was concluded that "...the levels \[of BOX A, BOX B, and MVM\] so far observed have been too low to allow definitive identification." and "Preliminary data suggest that these or similar compounds are present in the CSF of SAH patients" ([@B22]). Additional limitations of the study ([@B22]) included that the (1) source of CSF was not differentiated with respect to SAH patients symptomatic and asymptomatic for vasospasm and (2) quantitation of the amounts of (unconfirmed) BOX A and BOX B represented by the peaks could not be calculated due to the absence of their reported extinction coefficients (𝜀). Further, the MVM 𝜀 had not been established in solvent which eluted MVM from the reverse-phase HPLC column (acetonitrile:water; [@B22]) and was restricted to earlier determinations in methanol (2,290, λ~max~ 319 nm and 2,300, λ~max~ 317 nm; [@B2]; [@B23]).

The limitations of this earlier report of elevated BOXes in the CSF of SAH patients ([@B22]) were at least partially overcome in a subsequent study ([@B28]) in which (1) a comparison was performed between total BOXes levels in CSF extract from SAH patients asymptomatic and symptomatic for vasospasm, in which CSF only from symptomatic patients elicited constriction, and (2) total BOXes formation was estimated, with total BOXes CSF levels in asymptomatic patients at or below the lower limit of detection (0.007 μM was the lowest BOXes concentration reported) and in symptomatic patients total BOXes concentrations consistently somewhat greater than 1 μM ([@B28]; caveats associated with these concentration measurements discussed directly below). Moreover, the lower levels of BOXes in CSF from SAH patients asymptomatic for vasospasm was attributed to the comparatively lesser formation of bilirubin and weaker oxidizing environment, as based upon the lower CSF levels of malonyldialdehyde and peroxidized lipid ([@B28], [@B30]). It should also be noted that bilirubin acts as a reducing agent ([@B14]). Thus, the greater oxidizing environment in CSF from SAH patients symptomatic for vasospasm occurred despite the greater CSF levels of bilirubin ([@B9]).

In any case, due to the absence of sufficient purified compound, mole determinations were based upon a collective extinction coefficient (𝜀; 6,985 L/mol-cm^-1^) approximated using the absorption at 310 nm of a saline-reconstituted, chloroform extract of a hydrogen peroxide--bilirubin reaction mixture containing BOX A, BOX B, and MVM ([@B40]). Caveats associated with adoption of absorption at 310 nm include that there was some variability in the amounts of these BOXes species formed and, in particular, varied formation of MVM ([@B40]). This variability would influence the 𝜀 approximation because the λ~max~ for MVM is 317 or 319 nm, at least as determined in methanol (as noted above; [@B2]; [@B23]). Also, the λ~max~'s for BOX A and BOX B in saline are 300 and 310 nm, respectively ([@B22]).

A second caveat associated with the approximated 𝜀 ([@B40]) is that the determination was based upon an estimated 50% conversion of bilirubin to BOXes by the hydrogen peroxide oxidation of bilirubin, with the remaining 50% unreacted bilirubin and biliverdin as well as "other compounds" that do not absorb at 310 nm ([@B22]; [@B28]; [@B40]).

Finally, utilizing the approximated 𝜀 determined by total BOXes in a reconstituted chloroform extract of a hydrogen peroxide--bilirubin reaction mixture ([@B40]) assumes that this product composition mimics the composition of endogenously formed BOXes. In this regard, the ratio of endogenous *Z*-BOX A:*Z-*BOX B is 1:1, as determined in human, rat, and mouse serum, and human bile and gallstones, as compared to 2:1 in the hydrogen peroxide--bilirubin reaction mixture (BOX A and BOX B can exist as *Z* and *E* regio-isomers, the *E* regio-isomers are not formed in the hydrogen peroxide--bilirubin reaction mixture; [@B36], [@B35]; [@B32]; **Figure [1](#F1){ref-type="fig"}**). Also, it should be considered that relative amounts and species of endogenous BOXes formed may change with time post-SAH, the magnitude of SAH as well as factors that influence BOXes formation.

More recently, constriction of rat arteries in a cranial window preparation in response to CSF (unextracted) from two patients symptomatic for vasospasm was attributed to BOXes based on the (1) absorption of the CSF at 320 nm and (2) decreased constriction of arterioles of rat cortex, determined in a cranial window, following degradation (decreased amount of 320 nm absorption) of BOXes with exposure of the CSF to visible light (380--760 nm, 25 watts and 150 cm distance from sample; [@B33]). The attribution of BOXes degradation to the light-induced decrease in CSF-mediated constriction ([@B33]) was based upon earlier findings that ambient (t~1/2~ 10 h), sun-, and UV light caused decreased absorption of BOX A and BOX B in a reconstituted extract of a hydrogen peroxide--bilirubin reaction mixture ([@B22]; [@B6]; [@B40]). Also, 30 min sunlight exposure isomerized *Z*-BOX A and *Z*-BOX B to their respective *E* regio-isomers and 8 h exposure caused considerable degradation ([@B36]).

Exogenous Boxes
===============

Prior to 2014, by which time the complete chemical syntheses of both BOX A and BOX B had been reported ([@B21]; [@B34], respectively), and beginning with the initial report of BOXes ([@B22]), the exogenous BOXes preparation used to determine biologic activity was derived from a lyophilized, 10% hydrogen peroxide--bilirubin reaction mixture (24 h incubation) reconstituted in physiologic saline. The reconstituted reaction mixture contained BOX A, BOX B, and MVM and, furthermore, at a 1.7:1.2:1 ratio ([@B40]). This ratio was determined at the single wavelength of 320 nm (reversed-phase HPLC in acetonitrile/water eluate; [@B40]) and, thus, reflects an approximation given the differing λ~max~'s/𝜀's for these BOXes ([@B2]; [@B23]; [@B22]; [@B21]; [@B17]) and the variability in the amounts of these BOXes species formed in the hydrogen peroxide--bilirubin reaction mixture (see above; [@B40]). It should also be noted that the preparation presumably contained contaminants which did not absorb at 310 nm ([@B40]).

The earliest report of BOXes-induced constriction utilized an *in vitro* preparation of the pig carotid artery and 1 mg/ml of BOXes ([@B22]). The amount of actual BOXes was, in fact, significantly less than 1 mg/ml because the weight determination also included sodium chloride (originating from hydrochloric acid neutralization of the sodium hydroxide used to solubilize the bilirubin for oxidation by hydrogen peroxide; [@B22]). An additional consideration is that the BOXes preparation consisted of a saline reconstituted, lyophilized hydrogen peroxide--bilirubin reaction mixture ([@B22]). Thus, it was assumed that the hydrogen peroxide, which can elicit constriction, was removed by lyophylization ([@B22]). As a control for possible contaminant effects, the extract was exposed to sunlight (90 min) to degrade BOX A, BOX B, and MVM (as described above in "Endogenous BOXes; [@B22]; [@B6]; [@B40]; [@B36]). Indeed, sunlight decreased the biological activity of the reconstituted BOXes mixture ([@B22]). While the decreased biologic activity of the reconstituted BOXes mixture due to sunlight also appears consistent with the activity of the BOXes preparation not involving possible remaining peroxides, on the other hand it should be considered that sunlight/UV light degrades hydrogen peroxide.

In apparent contrast to this earlier finding that reconstituted BOXes mixture constricted pig carotid artery ([@B22]; note that CSF extract also constricted pig carotid artery; [@B26], [@B27]; [@B29]), a subsequent study with this vessel *in vitro* failed to demonstrate constriction in response to a BOXes mixture approximated at 20 μM (calculated with an estimated 𝜀 of 6,985 L/mol-cm^-1^ derived as described above in "Endogenous BOXes"; [@B29]). While the reason underlying these apparently contrasting findings is not clear, a possible explanation is that the BOXes preparation utilized in the subsequent study was extracted with chloroform prior to use ([@B29]). Specifically, the hydrogen peroxide--bilirubin reaction mixture that had been neutralized with hydrochloric acid and then lyophilized was extracted with chloroform and then dried under nitrogen prior to saline reconstitution ([@B29]). Chloroform extraction would have substantially reduced the amount of sodium chloride in the BOXes preparation ([@B29]) as well as possible hydrogen peroxide remaining following lyophilization.

Despite the inability of the reconstituted BOXes mixture to constrict the pig carotid artery in this subsequent study, the mixture elicited a non-selective increase in contractile sensitivity of this vessel ([@B9]; [@B29]). Specifically, the BOXes mixture enhanced contractions to phenylephrine, histamine, and KCl ([@B9]; [@B29]). The mechanism underlying the enhanced constriction may have been due to the observed BOXes-mediated increased activity of protein kinase C α and δ and Rho A, while purified protein phosphatase 1 activity remained unaltered ([@B29]). It should also be noted that CSF extract of SAH patients symptomatic for vasospasm activated protein kinase C α and δ and Rho A ([@B29]). The mechanism whereby the reconstituted BOXes mixture, as well as the CSF extract of SAH patients symptomatic for vasospasm, activate these two signaling pathways remains to be determined.

With respect to BOXes constriction of cerebral vessels, in a cranial window placed over the rat parietal cortex, differing effects of the supradural application (single dose) of a reconstituted BOXes mixture on vascular tone were observed depending on the dilution of the BOXes containing solution ([@B8]). While the least dilution (greatest concentration) of the BOXes mixture caused dilation and the greatest dilutions lacked both constrictor and dilator efficacy, intermediate dilutions caused constriction ([@B8]; vehicle controls not reported). The constriction was relatively slow to develop, i.e., 40 min, and was still present at 24 h ([@B8]), consistent with the prolonged vasospasm observed with SAH ([@B10]; [@B37]; [@B12]; [@B15]).

Possibly related to the mechanism underlying the reconstituted BOXes mixture-induced constriction ([@B22]; [@B8]), a BOXes mixture rapidly and concentration-dependently (1--100 μM, estimated with the approximated 𝜀 derived in [@B40]) diminished the open probability of Slo1 K^+^ channels as determined by patch clamp of myocytes isolated from the mouse basilar artery and branches ([@B18]). The BOXes mixture utilized by [@B18] was reported as containing BOX A:BOX B:MVM at a 2:2:1 ratio, a ratio presumably based upon relative peak absorption at 310 nm ([@B40]). Sunlight prevented the effect of the reconstituted BOXes mixture on Slo1 K^+^ channels, consistent with the action of BOXes rather than a contaminant ([@B18]). The BOXes mixture was effective when added to either the extracellular or cytoplasmic side, although the response was more rapid on the latter ([@B18]). Additionally, the effect of BOXes was slow to reverse ([@B18]). These findings of [@B18] are consistent with the ability of BOXes to traverse the membrane to act at a cytoplasmic site of Slo1 K^+^ channels and, further, the sustained constriction following supradural application of BOXes ([@B8]), the resistance to reversal of the constriction of cerebral vessels in brain slices (see below; [@B19]), and the prolonged vasospasm following SAH ([@B10]; [@B37]; [@B13]; [@B12]; [@B15]). In addition to a direct inhibitory effect of BOXes on Slo1 K^+^ channels ([@B18]), BOXes activation of protein kinase C ([@B29]) may represent an additional signaling pathway for Slo1 K^+^ channel inhibition. In support of this suggestion are demonstrations of protein kinase C inhibition of Slo1 K^+^ channel inhibition in vascular smooth muscle, although protein kinase C activation of Slo1 K^+^ channel has also been reported ([@B20] and references therein).

More recently, in mouse brain slices, 5 μM *Z*-BOX A (purified by reversed-phase HPLC) constricted intracerebral arterioles (pre-constricted with a nitric oxide synthase inhibitor) of the visual cortex ([@B19]). In comparison, 5 μM *Z*-BOX B (purified by reversed-phase HPLC) was much less efficacious and elicited a slower time course for constriction (although the possibility was raised that a longer period of *Z*-BOX B exposure could potentially elicit a greater magnitude of constriction; [@B19]). The *Z*-BOX A-induced plateau constriction required approximately 1 h to develop and was maintained for at least 30 min following washout ([@B19]), findings qualitatively similar to the relatively slow onset of constriction and maintained constriction of superficial vessels of the rat parietal cortex following supradural application of a single dose of BOXes mixture ([@B8]). Also, consistent with the ability of the BOXes mixture to diminish the open probability of Slo1 K^+^ channels ([@B18]), Slo1 K^+^ channel knockout prevented *Z*-BOX A-induced arteriolar constriction ([@B19]). The ability of *Z*-BOX A to elicit constriction appears to be vessel specific in that *Z*-BOX A failed to increase pressure in an isolated liver perfusion preparation of the rat ([@B35]).

In terms of possible additional targets for BOXes, in hepatocytes *Z*-BOX A and *Z*-BOX B were cytotoxic, initiated cytoskeletal remodeling, influenced the glutathione redox state, modulated *Rev-erb*α/β activity (regulation of metabolism of endogenous and exogenous compounds), and decreased CYP7A1 in its capacity as the rate limiting enzyme in the synthesis of bile acids ([@B35]). However, whether any of these findings in hepatocytes are transferrable to the pathobiologies associated with BOXes in SAH remains for further investigation.

Conclusion, Speculations, and Future Directions
===============================================

Findings support the presence of BOXes in the CSF of SAH patients and, moreover, are associated with CSF from patients symptomatic for vasospasm ([@B28]; [@B33]). Further, it appears that the concentration of BOXes in the CSF of these patients is sufficient to contribute to the vasospasm ([@B28]; [@B33]). Clearly, the concentrations of the different BOXes species and the time courses for their formation remain to be established. Along these lines, it was estimated that total BOXes formation in patients symptomatic for vasospasm was approximately 1 μM ([@B28]), a concentration in a similar range as the concentration of *Z*-BOX A that constricted intracerebral arterioles in brain slices of the mouse visual cortex ([@B19]). It should also be considered that additional BOXes species are vasoactive as well as enhance constriction to other agonists which are associated with SAH-induced vasospasm ([@B9]; [@B29]), including endothelin-1 ([@B10]).

Interestingly, there was a log-log (linear), 1000:1 correlation between bilirubin and *Z*-BOX A plus *Z*-BOX B plasma levels, with the greatest bilirubin concentration assayed approximately 0.6 μM, as determined in healthy humans and patients with cholestatic liver failure and hereditary deficiency of bilirubin glucuronidation in rats ([@B35]). Based upon the amount of bilirubin in the CSF of SAH patients symptomatic for vasospasm of approximately 30 μM ([@B28]) and extrapolation of the correlation between bilirubin and *Z*-BOX A plus *Z*-BOX B plasma levels ([@B35]) it would be predicted that 30 nM *Z*-BOX A plus *Z*-BOX B is present in the CSF of these patients. Also, with accounting for the lack of vasoconstrictor activity of *Z*-BOX B, the predicted concentration of *Z*-BOX A in CSF from SAH patients symptomatic for vasospasm would be approximately two orders of magnitude less than the concentration which constricted intracerebral arterioles in brain slices of the mouse visual cortex (5 μM; [@B19]). A likely explanation for this difference in predicted concentration of *Z*-BOX A and the concentration which elicited arteriole constriction in brain slices ([@B19]) is that the cerebral oxidizing environment following SAH in these patients ([@B28], [@B30]) is considerably greater than the oxidizing environment in the liver under the conditions which demonstrate a 1000:1 correlation between bilirubin and *Z*-BOX A plus *Z*-BOX B ([@B35]).

In terms of the presence of BOXes species in biologic compartments in addition to CSF following SAH, it would be anticipated that levels of BOXes in the CSF reflect those in the blood clot and, moreover, at least at relatively earlier times post-blood clot formation are present in the clot at a comparatively higher concentration than the CSF. Also, the lipid solubility of BOXes, as evidenced by extraction in chloroform ([@B22]; [@B9]; [@B40]; [@B32]; [@B17]), as well as the ability of supradural application of BOXes to access superficial cortical vessels ([@B8]), i.e., a phenomenon which requires traversal of BOXes through the dura and arachnoid membranes ([@B1]), and the octanol/water partition coefficients (log P~OW~) of *Z*-BOX A and *Z*-BOX B of 0.92 and 1.11, respectively (solubility in water of 103.6 and 76.4 mg/ml, respectively; [@B35]), suggest that BOXes derived from the clot can accumulate in the tissues. Of some possible relevance to this suggestion are findings with intracellular hemorrhage in a pig model, in which the perihematomal tissue demonstrated elevated levels of BOXes ([@B5]). On the other hand, recovery of *Z*-BOX A and *Z*-BOX B from plasma was 90 and 92%, respectively, utilizing a polar solvent (acetonitrile:water, 2:98 v/v; [@B36]).

It should also be anticipated that the formation of different BOXes species (with varying constrictor potencies and efficacies), as well as their levels of formation, depends upon the magnitude/site of injury. Thus, the species and levels formed would depend upon the oxidative environment. In this regard, propentdyopents, precursor isomers of *Z*-BOX A and *Z*-BOX B, were formed as a result of bilirubin oxidation with a lower concentration of hydrogen peroxide (1% as compared to 10%) and, moreover, were detected in human gallstones and bile of patients undergoing cholystectomy ([@B32]). Furthermore, propentdyopents levels were significantly greater than *Z*-BOX A and *Z*-BOX B levels in the bile of these patients ([@B32]). More recently, the formation of "*Z*-BOX C", a propentdyopent product, was detected in bile from patients with cholecystectomy ([@B31]). Thus, it would be of interest whether the propentdyopents and *Z*-BOX C are efficacious vasoconstrictors, in addition to other possible effects. Additionally, oxidation of bilirubin with storage (4 and 37°C for 2 and 7 days) resulted in the formation of BOXes species other than BOX A, BOX B, MVM and propentdyopents, and which remain unidentified ([@B24]; [@B32]). Intracerebral infusion of this BOXes preparation combined with bilirubin elicited greater pathobiologic effects than bilirubin alone ([@B24]). Thus, it is also possible that one or more of the BOXes formed upon storage possess vasoconstrictor activity. Further, as the oxidative environment in SAH is influenced by the amount of hemorrhage, it would be predicted that the formation of different BOXes species depends upon the amount of blood clot formation.

It may also be considered that the vasoconstriction (as well as other effects) elicited by crude extract of the bilirubin-hydrogen peroxide reaction mixture ([@B9]; [@B30]), could have been at least partly *Z*-BOX A-mediated based on the (1) selective cerebral vasoconstrictor effect of *Z*-BOX A and (2) preferential formation of *Z*-BOX A as compared to *Z*-BOX B (2:1) by hydrogen peroxide (10%) oxidation of bilirubin ([@B35]). Further, the estimated concentrations of BOXes mixture which constricted cerebral arterioles in a cranial window (20 μM; [@B8]) and decreased Slo1 K^+^ channel opening (1--100 μM; [@B18]), are within the range of the *Z*-BOX A concentration that constricted arterioles in brain slices (5 μM; [@B19]).

In terms of the mechanism underlying BOXes-induced vasoconstriction, the (1) relatively slowly developing contractile response and maintained constriction elicited by *Z*-BOX A ([@B19]) and BOXes mixture ([@B8]) and (2) ability of BOXes mixture to traverse the extracellular membrane to a cytoplasmically located portion of the Slo1 K^+^ channel and also slow reversal of the BOXes effect on this channel ([@B18]), may suggest that the efficacious BOXes species, as the result of its lipid solubility \[e.g., octanol--water partition coefficients (log P~OW~) for *Z*-BOX A and *Z*-BOX B of 0.92 and 1.11, respectively; [@B22]; [@B40]; [@B35]\], becomes inserted into the plasma membrane whereupon it acts at a specific site. Further, the maintained constriction could result from the continued inhibition (e.g., the diminished probability of Slo1 K^+^ channel opening; [@B18]; [@B19]) of this signaling mechanism due to the continued presence of the BOXes species in the membrane. As an additional speculation, the membranal insertion of *Z*-BOX A would also prevent its further oxidative-induced degradation, thereby also contributing to a prolonged effect.

With respect to the concentration-dependent selectivity of BOXes, the ability of \>100 μM of both *Z*-BOX A and *Z*-BOX B to increase hepatocyte toxicity suggest that higher concentrations of *Z*-BOX A lack selectivity ([@B35]). On the other hand, \>100 μM concentrations of *Z*-BOX A, but not *Z*-BOX B, caused morphological changes in the HepG2 cells ([@B35]). These results, along with the finding that *Z*-BOX A constricts cerebral vessels ([@B19]), but not hepatic arteries ([@B35]), suggest that *Z*-BOX A and *Z*-BOX B action depends upon different targets with differing affinities. Along these lines, whether the inability of *Z*-BOX A to increase liver perfusion pressure ([@B35]) is due to a relative minimal number of Slo1 K^+^ channels in hepatic resistance vessels also remains for consideration.

Laying the groundwork for filling these gaps are recent notable advances in this field, including total synthesis of the *Z*-BOX regio-isomers ([@B21]; [@B34]). Amongst other advances, this synthesis would assist in the isotopic labeling of significant amounts of these regio-isomers for binding studies. Also, the recently developed sensitive assays for the *Z*-BOX regio-isomers and the novel precursors to *Z*-BOX A and *Z*-BOX B, the propentdyopents, will provide measurements of endogenous formation and concentrations of these BOXes in relevant biologic compartments ([@B36]; [@B32]). Filling these gaps will assist in determinations of the mechanism of BOXes-induced vasoconstriction and, thus, the eventual development of pharmacologic agents which selectively antagonize the constriction as well as other pathobiologic effects.
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